IN2015DN00372A - - Google Patents

Info

Publication number
IN2015DN00372A
IN2015DN00372A IN372DEN2015A IN2015DN00372A IN 2015DN00372 A IN2015DN00372 A IN 2015DN00372A IN 372DEN2015 A IN372DEN2015 A IN 372DEN2015A IN 2015DN00372 A IN2015DN00372 A IN 2015DN00372A
Authority
IN
India
Prior art keywords
met
synthesis
treating
formula
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Shaojing Hu
Fei Wang
Zhiguo Xu
Yanping Wang
Yinxiang Wang
Original Assignee
Zhejiang Beta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Beta Pharmaceuticals Co Ltd filed Critical Zhejiang Beta Pharmaceuticals Co Ltd
Publication of IN2015DN00372A publication Critical patent/IN2015DN00372A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IN372DEN2015 2012-06-29 2013-07-01 IN2015DN00372A (h)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2012077924 2012-06-29
PCT/CN2013/078592 WO2014000713A1 (en) 2012-06-29 2013-07-01 NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
IN2015DN00372A true IN2015DN00372A (h) 2015-06-12

Family

ID=49782283

Family Applications (1)

Application Number Title Priority Date Filing Date
IN372DEN2015 IN2015DN00372A (h) 2012-06-29 2013-07-01

Country Status (14)

Country Link
US (1) US9617257B2 (h)
EP (1) EP2867223B1 (h)
JP (1) JP6059342B2 (h)
KR (3) KR101726555B1 (h)
AU (1) AU2013283993B2 (h)
BR (1) BR112014032745B1 (h)
CA (1) CA2878049C (h)
ES (1) ES2698511T3 (h)
IN (1) IN2015DN00372A (h)
RU (1) RU2619130C2 (h)
SG (1) SG11201408750VA (h)
TW (1) TWI520962B (h)
WO (1) WO2014000713A1 (h)
ZA (1) ZA201500344B (h)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279147A (zh) * 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
KR20180030026A (ko) * 2015-07-20 2018-03-21 베타 파머수티컬 컴퍼니 리미티드 융합된 피리딘 유도체의 말레에이트의 결정질 형태 및 이의 용도
CN106924260B (zh) * 2015-12-31 2018-05-25 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
CN118994190A (zh) 2016-02-05 2024-11-22 戴纳立制药公司 受体相互作用蛋白激酶1的抑制剂
HUE058802T2 (hu) 2016-12-09 2022-09-28 Denali Therapeutics Inc RIPK1 inhibitorokként alkalmas vegyületek
WO2018215668A1 (en) * 2017-05-26 2018-11-29 Glenmark Pharmaceuticals S.A. Novel inhibitors of map4k1
JP7131837B2 (ja) * 2017-06-19 2022-09-06 アビスコ セラピューティクス カンパニー リミテッド Csf-1r阻害活性を有するアザアリール誘導体、その製造方法および応用
CN109988108B (zh) * 2017-12-29 2022-04-29 江苏豪森药业集团有限公司 一种卡博替尼的制备方法
KR20210111779A (ko) * 2018-12-14 2021-09-13 베타 파마, 인크. C-met 억제제로서 유기 인-치환 화합물 및 이의 치료학적 용도
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TWI812302B (zh) * 2021-06-24 2023-08-11 南韓商Lg化學股份有限公司 作為ron抑制劑之新穎尿素衍生物化合物
AU2023206890A1 (en) 2022-01-12 2024-08-22 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
EP4289427A1 (en) * 2022-06-10 2023-12-13 Anagenesis Biotechnologies Dihydro[1,8]naphthyridin-7-one and pyrido[3,2-b][1,4]oxazin-3-one for use in treating cancer, and metastases in particular.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005389A2 (en) 2003-07-07 2005-01-20 Merck Patent Gmbh Malonamide derivatives
DE10357510A1 (de) * 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroarylsubstituierte Benzole
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2006014325A2 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
EP1781664B1 (en) * 2004-07-30 2013-09-04 MethylGene Inc. Inhibitors of vegf receptor and hgf receptor signaling
EP1827434B1 (en) * 2004-11-30 2014-01-15 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
AU2006313456B2 (en) 2005-05-20 2011-06-23 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
EP2079738A2 (en) * 2006-10-27 2009-07-22 Glaxo Group Limited 7-azaindole derivatives as c-met kinase inhibitors
US7960567B2 (en) 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
KR100961410B1 (ko) * 2008-10-14 2010-06-09 (주)네오팜 단백질 키나제 억제제로서 헤테로사이클릭 화합물
AU2009303602B2 (en) * 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
CN102086211B (zh) * 2009-12-08 2013-09-11 广东东阳光药业有限公司 作为蛋白激酶抑制剂的芳杂环化合物
JP5770281B2 (ja) * 2010-07-14 2015-08-26 ベータ ファーマシューティカルズ カンパニー リミテッド c−METチロシンキナーゼ阻害薬として有用な新規な縮合複素環式誘導体

Also Published As

Publication number Publication date
CA2878049A1 (en) 2014-01-03
ZA201500344B (en) 2016-08-31
RU2015102057A (ru) 2016-08-20
KR20170017014A (ko) 2017-02-14
TW201418254A (zh) 2014-05-16
SG11201408750VA (en) 2015-01-29
KR101770545B1 (ko) 2017-08-22
EP2867223A4 (en) 2016-01-06
JP6059342B2 (ja) 2017-01-11
JP2015521634A (ja) 2015-07-30
KR20150031320A (ko) 2015-03-23
ES2698511T3 (es) 2019-02-05
RU2619130C2 (ru) 2017-05-12
KR101726522B1 (ko) 2017-04-12
BR112014032745A2 (pt) 2017-06-27
TWI520962B (zh) 2016-02-11
US9617257B2 (en) 2017-04-11
BR112014032745B1 (pt) 2022-01-04
EP2867223B1 (en) 2018-09-05
AU2013283993A1 (en) 2015-02-05
AU2013283993B2 (en) 2016-07-07
KR101726555B1 (ko) 2017-04-12
HK1207642A1 (en) 2016-02-05
EP2867223A1 (en) 2015-05-06
WO2014000713A1 (en) 2014-01-03
CA2878049C (en) 2016-12-13
KR20170017015A (ko) 2017-02-14
US20150315210A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
IN2015DN00372A (h)
PH12017502141A1 (en) Compounds and their methods of use
GEP201706688B (en) Cdk8/cdk19 selective inhibitors and their use in anti- metastatic and chemopreventative methods for cancer
MY191796A (en) Heterocyclic compounds as lsd1 inhibitors
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
TR201816379T4 (tr) DNA-PK inhibitörleri.
NZ726859A (en) Synthesis of polycyclic-carbamoylpyridone compounds
GEP20156372B (en) Pyridazinone compounds and their use as daao inhibitors
IN2015DN01151A (h)
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
IN2014CN03072A (h)
TN2015000120A1 (en) Oxazolidin-2-one-pyrimidine derivatives
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
CR20140528A (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de Bace1
TN2013000420A1 (en) 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors
MX365315B (es) Derivados de piridina sustituidos útiles como inhibidores de c-fms quinasa.
CY1119470T1 (el) Γαλακταγωγες συνθεσεις με βαση φωσφατιδυλοσερινη
IN2015DN00950A (h)
IN2014DN08443A (h)
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
IN2013MU01290A (h)
MX2014002378A (es) Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma.
MX391523B (es) Intermediarios y metodos para sintetizar derivados de calicheamicina
NZ743260A (en) Bipiperidine-2-one compounds for the preparation of pyrimidinyl tyrosine kinase inhibitors